Jounce Therapeutics Reports Improved PFS and OS Associated with Vopratelimab (JTX-2011) Treatment Emergent Biomarker at the 2019 ...
- Improved PFS and OS observed in patients treated with vopratelimab who have emergence of ICOS hi CD4 T cells compared to patients with ICOS lo CD4 T cells - - ICOS hi CD4 T cells demonstrate distinct, activated T effector cell characteristics - - Company …